Dendreon Corp fka DNDNQ

[ghmm]

FYI I follow United Therapeutics quite a bit (The Remodulin Franchise is Key OvaRex would be a big bonus in my book) and the Posters they had at their Analysts/Investor day did show that OvaRex K-M curves separate on the 5 year survival data for both the overall treatment group and the Successful Front Line Therapy (SFLT) group (which is the retrospective subset they are basing the Phase 3 patient population on). Though it is notable that the p values are not statistically significant .2756 (Overall) and .1121 SFLT subset.

EDIT: I mention it because I believe OvaRex could be classified as an immunotherapy.

Another EDIT: Forgot to mention the most important thing! Going along with your discussion about separating late that is what appears in both curves (about 18-24 months they begin to separate)